Roy Baynes, Merck

Mer­ck­'s 15-strain pneu­mo­nia shot match­es Pre­vnar 13 in late-stage in­fant study, but Pfiz­er's next-gen shot looms

In or­der to keep the heat on Pfiz­er and its next-gen­er­a­tion pneu­mo­coc­cal vac­cine, Mer­ck knows it will need to get cre­ative to give its 15-serotype shot a fight­ing chance. In­fant pa­tients could hold the key, and new da­ta con­tin­ue to sup­port Mer­ck’s case there.

Mer­ck’s Vaxneu­vance, a next-gen, 15-va­lent shot, matched Pfiz­er’s block­buster Pre­vnar 13 in terms of dri­ving im­muno­genic­i­ty across 13 shared serotypes and on the safe­ty front, ac­cord­ing to da­ta from the Phase III PNEU-PED study re­vealed Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.